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The potential applications of human embryonic stem cells (hESCs) in regenerative medicine and
developmental research have made stem cell biology one of the most fascinating and rapidly expanding
ﬁelds of biomedicine. The ﬁrst clinical trial of hESCs in humans has begun, and the ﬁeld of stem cell
therapy has just entered a new era. Here, we report seven hESC lines (SEES-1, -2, -3, -4, -5, -6, and -7).
Four of themwere derived and maintained on irradiated human mesenchymal stem cells (hMSCs) grown
in xenogeneic-free deﬁned media and substrate. Xenogeneic-free hMSCs isolated from the subcutaneous
tissue of extra ﬁngers from individuals with polydactyly showed appropriate potentials as feeder layers
in the pluripotency and growth of hESCs. In this report, we describe a comprehensive characterization of
these newly derived SEES cell lines. In addition, we developed a scalable culture system for hESCs having
high biological safety by using gamma-irradiated serum replacement and pharmaceutical-grade re-
combinant basic ﬁbroblast growth factor (bFGF, also known as trafermin). This is ﬁrst report describing
the maintenance of hESC pluripotency using pharmaceutical-grade human recombinant bFGF (tra-
fermin) and gamma-irradiated serum replacement. Our deﬁned medium system provides a path to
scalability in Good Manufacturing Practice (GMP) settings for the generation of clinically relevant cell
types from pluripotent cells for therapeutic applications.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Human pluripotent stem cells such as human embryonic stem
cells (hESCs) and induced pluripotent stem cells (iPSCs) have
remarkable developmental plasticity and therefore possess great
potential for drug screening and the development of cellular
models to study diseases. hESCs also have potential applications in
regenerative medicine as source for cell-based therapy. Since the
initial derivation of pluripotent hESCs by Thomson and colleagues: þ81 3 5494 7048.
(A. Umezawa).
se Society for Regenerative
tion Research Institute, New
ative Medicine. Production and hoin 1998 [1], more than 1000 hESC lines have been established and
are now utilized in basic and clinical research worldwide [2].
Several clinical trials using hESC lines approved by the United
States Food and Drug Administration (FDA) are currently underway.
However, further research is still needed to facilitate the develop-
ment of safer, reproducible, and scalable culture systems for the
generation of hESCs for clinical and industrial purposes.
A key consideration with a cell therapy-compliant culture sys-
tem, including safe expansion of hESCs, is the choice of culture
media, matrix (including feeder layers), and passage procedures.
Early hESC culture systems typically include the use of mouse
embryonic ﬁbroblast (MEF) feeders or medium conditioned on
MEFs in the presence of serum or serum substitutes such as
knockout serum replacement [1,3e6]. Human feeders and serum
have also been used for hESC culture [7]; however, the use of serum
or serum replacement, which contains undeﬁned xenogeneicsting by Elsevier B.V. All rights reserved.
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cells. Transplantation of human cells exposed to animal-derived
products can potentially transfer immunogenic sugars such as N-
glycolylneuraminic acid (Neu5Gc) into the human body and may
trigger chronic inﬂammation and immune reactions [8e10]. Recent
studies have identiﬁedmultiple factors that play a role in sustaining
pluripotency and have led to the development of several deﬁned
medium systems for hESC culture and derivation [11e13]. Because
no reports have described the successful establishment of hESCs in
xenogeneic-free (XF) medium, it seems realistic to assume that the
most reliable strategies for the establishment of clinical-grade
hESCs include the use of a human feeder layer in XF medium, fol-
lowed by expansion in a feeder-free culture system [14]. There are
two strategies for developing hESC culture systems suitable for
generation of clinically applicable cells. One approach is to establish
XF, deﬁned culture systems especially for future applications, and
the other approach is to develop safe conditions for hESC culture
systems while continuing to use xenogeneic products. In fact,
ongoing clinical trials using hESCs employ conventional hESC cul-
ture systems, including mouse feeder layers, under certain condi-
tions [15].
In this study, we developed a novel derivation/cultivation sys-
tem of hESCs for potential application in translational and clinical
research. To completely avoid exposure of hESCs to culture media
with animal products, we established an XF culture system con-
taining XF, deﬁned culture medium with inactivated human
mesenchymal stem cell (hMSC) feeders. The XF culture systemwith
the hMSC feeder layers proved stable maintenance of self-renewal
and pluripotency of newly established hESCs for more than 50
passages. Here, we report the successful derivation of four new
hESC lines in this novel XF culture system. Furthermore, we eval-
uated replacement of a conventional hESC culture system with
high-dose gamma-irradiated serum and pharmaceutical-grade re-
combinant basic ﬁbroblast growth factor (bFGF) to provide insights
into the development of a reproducible hESC cultivation system.
We examined the pluripotency of SEES cell lines cultivated under
the modiﬁed conventional culture system. hESCs were able to
proliferate under the modiﬁed conventional conditions while
retaining their pluripotency. Thus, our data provided clinically
relevant alternative platforms for clinically and industrially appli-
cable hESC culture systems.Fig. 1. Derivation of human ES cells by immunosurgery and laser ablation A) The intact in
phectoderm are destroyed by brief exposure to antibodies directed against human cells in t
ESC (SEES-1) colony. B) The intact ICM was isolated by laser ablation without any animal pro
cells were targeted with multiple pulses of laser ablation. Typical morphology of ESC colo
isolation by laser ablation, which is commonly used in artiﬁcial reproductive technology (A2. Results
Since the ﬁrst report describing the generation of hESCs by
Thomson and coworkers [1], more than 1000 different hESC lines
have been established worldwide [2]. Nevertheless, there is still a
need for establishment of new hESC lines, particularly from certain
HLA types and ethnic groups [16]. In this study, we derived seven
new hESC lines using different culture conditions and developed a
new hESC culture system using gamma-irradiated KO-SR and
pharmaceutical-grade recombinant human bFGF (trafermin). Since
our organization name is “Sei-iku” in Japanese, the hESC lines were
designated as “SEES (Sei-iku embryonic stem)” in combinationwith
numbers.
2.1. Stable derivation and culture of hESCs under serum
replacement conditions
Out of ﬁve blastocysts, three hESC lines (SEES-1, SEES-2, and
SEES-3) were derived from ICMs on MEF layers using the immu-
nosurgery technique; conventional medium conditions, composed
of HUES medium without human plasma protein fraction [4]
(Fig. 1A), were used in this derivation. The pluripotency of each of
these three SEES cell lines was conﬁrmed by observation of typical
morphology and positive immunostaining of stemness markers
and differentiated derivatives comprising three embryonic germ
layers (Supplemental Figs. 1 and 2). G-banding showed that SEES-1,
SEES-2, and SEES-3 cells had normal karyotypes, i.e., 46,XX, 46,XX,
and 46,XY, respectively (Supplemental Fig. 1).
2.2. Isolation and characterization of the XF hMSC feeder layer
Primary hMSCs isolated from subcutaneous tissue samples of
juvenile donors undergoing surgical procedures for polydactyly
were derived and expanded in a complete XF media system that
contained an XF supplement, LipoMax, on a humanized substrate,
CELLstart (Fig. 2A). Proliferation analysis was performed, and cell
morphology was observed by light microscopy to conﬁrm the
proliferation assay results. Our data showed that cells grown in
MSC-XF medium exhibited high proliferation rates and were self-
renewing (Fig. 2B). Flow cytometric characterization was per-
formed to compare surface marker expression characteristics of thener cell mass (ICM) was isolated from blastocysts by immunosurgery. Cells of the tro-
andem with complement activity. Attachment and outgrowth of the ICM grew into an
ducts. Outgrowth of the blastocyst grown on human MSC feeder layers. Trophectoderm
nies was readily visible at high magniﬁcation. The image shows a schematic of ICM
RT).
Fig. 2. Isolation and characterization of the xenogeneic-free hMSC feeder layer A) Primary human mesenchymal cells isolated from subcutaneous tissue of the polydactyly were
expanded in xenogeneic-free media. B) Cells grew well over PD 30 under xenogeneic-free conditions. Two differentially isolated cell lines (red circle and blue triangle) showed
similar cellular proliferation characteristics. C) Mesenchymal markers such as CD29, CD44, and CD90 were observed. D,E) The cells differentiated into adipogenic and osteogenic
cells.
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CD90 expression was observed, while CD117 and CD133 were not
detected (Fig. 2C). Cells differentiated into both adipogenic and
osteogenic cells (Fig. 2D and E). Taken together, our data demon-
strated that cells isolated from polydactyly tissues could be classi-
ﬁed as MSCs by ﬂow cytometry analysis of their surface markers
and evaluation of their multilineage differentiation potential.2.3. Derivation of new hESC lines in XF culture conditions
To derive an XF hESC line, we ﬁrst developed anXF culture system
using XF hMSC feeder layers. We optimized an XF hESC medium
composed of KO-DMEM supplemented with KO-SR XF, amino acids,
vitamin C, bFGF, and two other growth factors (IGF1 and heregulin)
[17]. All components of the mediumwere synthetic, recombinant, or
of human origin. As a preliminary step, we conﬁrmed the stable
cultivation of SEES-1, SEES-2, and SEES-3 cells on XF hMSC feeder
layers in XF hESC medium (data not shown). Twelve frozen human
embryos were thawed and cultured to the blastocyst stage, and of
these, eight blastocysts were used to derive XF hESC lines. Intact
blastocysts, without immunosurgery, were plated onto irradiated XF
hMSC layers in XF hESC medium. ICM isolation was carried out by
exposing TE cells to cell-lethal laser pulses from an XYClone laser
system (Fig. 1B). Finally, four XF hESC lines (SEES-4, SEES-5, SEES-6,
and SEES-7) were generated and maintained stably (Fig. 3). All of
these newly derived XF hESC lines were karyotyped regularly and
exhibited a normal diploid karyotype, i.e., 46,XX, 46,XX, 46,XY, and46,XX, respectively (Fig. 3). To assess the expression of a subset of
stemness markers, these cell lines were analyzed by immunocyto-
chemical staining; all XF SEES cell lines expressed the hESC markers
NANOG, OCT3/4, SOX2, SSEA4, and TRA1-60 (Fig. 4). We also
generated human iPSCs from XF Yub cells by over-expressing three
reprogramming factors under hXF culture conditions using XF hESC
medium and XF hMSC feeder layers. The XF human iPSCswere stably
maintained and expressed the hESC markers such as OCT3/4,
NANOG, SSEA4 and TRA1-60 (Supplemental Fig. 3).2.4. hESCs cultured for prolonged periods in XF culture medium
maintained their pluripotency and differentiation characteristics
To evaluate whether the newly derived XF SEES cell lines
maintained their pluripotency in vitro, we performed EBs assays.
EBs differentiated from the cells of SEES-4, SEES-5, SEES-6, and
SEES-7 cells expressed markers associated with the three major
germ layers: TUJ1 (ectoderm), aSMA (mesoderm), and AFP (endo-
derm; Fig. 5A). Additionally, in an in vivo pluripotency assay,
structures from all three germ layers were detected, including
neural tissues and pigmented epithelium (ectoderm), cartilage
(mesoderm), and gut epithelial tissues (endoderm; Fig. 5B). Sialic
acid was released from seven hESCs by acid hydrolysis and quan-
tiﬁed by DMB-HPLC. Neu5Gc levels were increased in SEES-1, SEES-
2, and SEES-3 cells, while the four XF SEES cell lines (SEES-4, SEES-
5, SEES-6, and SEES-7) either did not express Neu5GC at all or had
negligible levels of Neu5GC (Supplemental Fig. 4).
H. Akutsu et al. / Regenerative Therapy 1 (2015) 18e29 21The seven SEES cell lines were further characterized by short
tandem repeat (STR) analysis (Supplemental Table 1), HLA-DNA
typing (Supplemental Table 2), ABO typing (Supplemental
Fig. 5), and cytogenetic X-chromosome inactivation statusFig. 3. Derivation of xenogeneic-free hESCs on the hMSC feeder layer Under completely xeno
layer using the laser ablation system. Typical ESC morphology was readily visible. Alkaline p
SEES-4, SEES-5, SEES-6, and SEES-7 cells showed normal karyotypes: 46,XX, 46,XX, 46,XY,analysis (Supplemental Fig. 6). The distinct features of SEES cell
lines could be observed by STR and HLA proﬁling. SEES-2 and
SEES-5 were blood type OO, which is most suitable for cellular
transplantation.geneic-free conditions, four hESC lines were derived from the inactivated hMSC feeder
hosphatase (ALP) activity was detected in each SEES cell line. Chromosome analysis of
and 46,XX, respectively.
Fig. 4. Pluripotent marker expression of xenogeneic-free SEES cell lines In the undifferentiated state, xenogeneic-free SEES cell lines expressed markers characteristic of pluripotent
hESCs, including OCT4, NANOG, SOX2, SSEA4, and TRA1-60. SEES-4: scale bars are 200 mm; SEES-5: scale bars are 50 mm in OCT3/4 and TRA1-60 and 200 mm in SOX2 and SSEA4;
SEES-6: scale bars are 50 mm in OCT3/4 and SOX2 and 200 mm in SSEA4; SEES-7: scale bars are 200 mm.
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hESC culture conditions
To overcome the shortcomings of conventional approaches, we
determined which elements of conventional culture systems were
necessary and sufﬁcient for maintaining the pluripotency of hESCs.
In our modiﬁed conventional hESC culture medium, human re-
combinant bFGF and KO-SR were replaced by pharmaceutical-
grade recombinant human bFGF (trafermin) and high-dose
gamma-irradiated KO-SR, respectively. SEES-2 cells were stably
maintained on the qualiﬁed MEF layer in the modiﬁed medium
without antibiotics (Fig. 6A). Under these conditions, the colonies
expressed multiple pluripotency markers, including OCT3/4,
NANOG, SOX2, SSEA4, and TRA1-60, as demonstrated by immu-
nostaining (Fig. 6B). Interestingly, SEES-2 cells could differentiate
into derivatives of all three embryonic germ layers in vitro and
in vivo. The EB formation assay showed detection of TUJ1, aSMA,
and AFP by immunostaining (Fig. 6C). Additionally, differentiation
of the three germ layer in vivowas conﬁrmed by teratoma analysis
(Fig. 6D), and SEES-2 cells retained normal karyotypes following
extensive passaging in culture (Fig. 6E). Under these conditions,
cells were able to maintain pluripotency for over 20 passages, asconﬁrmed by positive expression of SSEA4, TRA1-60, and TRA1-80
and absence of SSEA1 expression (Fig. 7). Taken together, our data
demonstrated that the modiﬁed conventional hESC culture system,
based on replacement with high-dose gamma-irradiated KO-SR
and trafermin, maintained the pluripotency of hESCs. SEES-1 and
SEES-3 also retaining their pluripotency, as shown by morpholog-
ical analysis and immunostaining (Supplemental Fig. 7). Analysis of
the expression of several genes by qRT-PCR showed that hESCs
grown under conventional conditions and our modiﬁed conditions
exhibited highly similar gene expression patterns (Supplemental
Fig. 8). Additionally, FISH analysis of SEES cell lines showed that
three out of the ﬁve SEES cell lines were X-chromosome active.
3. Discussion
Traditional methods for isolating and expanding hESCs include
using MEFs as a feeder layer and supplementing medium with FBS
replacement. Conventional hESC culture systems are widely used
for both basic research and clinical trials under appropriate con-
ditions for ensuring safety [15]. Currently, there are at least two
options for further development of hESC cultivation systems for use
in regenerative medicine; these methods seek to achieve safe
Fig. 5. Differentiation of three germ layers of xenogeneic-free SEES cell lines A) SEES cells differentiated in vitro via EBs expressed markers of the primary germ layers. Immu-
nohistochemical analyses of markers of the ectoderm (TUJ1), mesoderm (aSMA), and endoderm (AFP) layers are shown. SEES-4: scale bars are 100 mm; SEES-5: scale bars are
200 mm for TUJ1 and 100 mm for aSMA and AFP; SEES-6: scale bars are 100 mm for TUJ1 and aSMA and 200 mm for AFP; SEES-7: scale bars are 100 mm. B) SEES cells differentiated
in vivo via teratoma formation. Hematoxylin and eosin staining revealed germ layer derivatives, such as neural tissues, pigmented epithelium (ectoderm), cartilage (mesoderm), and
gut epithelial tissues (endoderm). Scale bars are 200 mm.
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system. Future potential uses of hESCs in clinical and industrial
applications will require a reproducible, XF culture system. In this
study, we evaluated the replacement of a conventional hESC culture
system with high-dose, gamma-irradiated serum andpharmaceutical-grade recombinant bFGF (trafermin) in order to
address the reproducibility of hESC cultivation systems. hESCs
could be successfully maintained using modiﬁed conventional
medium supplemented with 35 KGy-irradiated KO-SR and tra-
fermin. Our data provided evidence supporting clinically relevant
H. Akutsu et al. / Regenerative Therapy 1 (2015) 18e2924alternative platforms of hESC culture for use in clinical and indus-
trial applications. This study also demonstrated the development of
a deﬁned, novel, efﬁcient culture system for the derivation of hESCs
from blastocyst ICMs and described the expansion andFig. 6. Characterization of the pluripotency of SEES-2 maintained using a modiﬁed conventi
qualiﬁed MEF feeder layer in the modiﬁed medium, which contained pharmaceutical-grade
without antibiotics. A) Typical hESC colony morphology was readily visible. ALP activity w
NANOG, SOX2, SSEA4, and TRA1-60. SEES-2 cells could differentiate into three embryonic
differentiated in vitro via EBs expressed markers of the primary germ layers, ectoderm (T
analysis of teratomas containing multidifferentiated tissues derived from SEES-2 cells.
(endoderm). E) Chromosomal analysis of SEES-2 cells cultivated through 16 passages usingmaintenance of hESCs in completely XF conditions on human
allogeneic MSC feeder layers. The XF culture system with XF hMSC
feeder layers can stably expand several hiPSC lines (data not
shown) and successfully allow the derivation of human iPSCsonal hESC culture medium SEES-2 cells were stably maintained over 20 passages on the
recombinant human bFGF (trafermin) and high-dose (35-K) gamma-irradiated KO-SR
as detected. B) SEES-2 cells expressed undifferentiated hESC markers, including OCT4,
germ layers in vitro and in vivo. Scale bars are 200 mm. C) SEES cells that had been
UJ1), mesoderm (aSMA), and endoderm (AFP). Scale bars are 100 mm. D) Histological
Pigmented epithelium (ectoderm), cartilage (mesoderm), and gut epithelial tissues
a modiﬁed conventional hESC culture medium showed a normal 46,XX karyotype.
Fig. 7. Expression of pluripotency markers in SEES-2 cells was maintained using a modiﬁed conventional hESC culture medium Flow cytometric analysis of hESC-speciﬁc marker
expression in SEES-2 cells. The isotype control is indicated by the blue line, and the unlabeled sample, which was used as a control, is indicated by the red line. Surface staining is
shown by the yellow line for SSEA4, SSEA1, TRA-1-60, and TRA-1-81.
H. Akutsu et al. / Regenerative Therapy 1 (2015) 18e29 25(Supplemental Fig. 3). These conditions are also quite applicable to
iPSC derivation and cultivation as well. Importantly, the develop-
ment of such an XF culture system primarily enables hESCs to
culture and expand in conditions that are totally devoid of forming
Neu5GC, a sialic acid glycan and xenogeneic antigen that can
potentially transform cells to obtain cancer phenotypes [18,19]. In
this culture system, we developed and successfully generated
completely Neu5GC-free hESC lines. Our four XF hESC lines (SEES-4,
SEES-5, SEES-6, and SEES-7) can be also stably cultivated under
alternative xenogeneic-free conditions. Nakagawa et al. reported a
novel culture system for derivation and expansion of hiPSCs with
the recombinant laminin-511 E8 fragment matrices and the
xenogeneic-free culture medium (StemFit™) [20]. Four XF SEES cell
lines were stably grown using the StemFit™medium under feeder-
free conditions (data not shown). The XF SEES cell lines would be
accustomed to being maintained in xenogeneic-free conditions
with ease, as these cell lines have been derived and expanded
under animal derived components-free conditions.
Pluripotent hESCs are isolated from preimplantation embryos
[1] and general characteristics of hESCs include ﬂat morphology,
dependence on FGF2 signaling, differentiation into three germ
layers in vitro and in vivo, and pluripotent markers expression
[21]. Numerous hESC lines have been derived [3]. It is indicated
that many of hESC lines differ in the manner in which they were
derived and maintained in culture, and such differences mayhave signiﬁcant effects on the characteristics of the cell lines
[22,23]. In female hESCs, culture conditions may have signiﬁcant
effects on the X chromosome inactivation status and contribute
to the cellular characteristics [24]. Three of ﬁve female SEES cell
lines showed none of XIST expression in this study. However, it
has demonstrated that there are not notable differences in gross
hESCs characters including pluripotent markers and differentia-
tion in vitro and in vivo, despite the signiﬁcant differences in XIST
expression status among SEES 1, 2, 4, 5 and 7. Notably, SEES cell
lines are characterized not only the biological properties of hu-
man ESCs, also the genomic signatures including ABO blood
typing, STR genotyping and HLA isotyping. The distinct proper-
ties of the SEES cell lines offer a scalable cell resource for clinical
application.
The culture medium we described in this study consisted of a
basal culture medium with well-known growth factors that deﬁne
the maintenance of pluripotency. Since these ingredients are well
known and are added to a simple culture medium formulation, the
cells derived/expanded in such a system have the potential for
reduced contamination, better kinetics of growth, good ability to
differentiate into all the three germ layer derivative lineages,
maintain a normal karyotype, and, most importantly, will not
contribute to tumorigenicity. This deﬁned culture system serves as
a better and safer alternative to derive/culture/expand hESCs/iPSCs
for larger cell therapy purposes.
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4.1. Derivation of hESC lines on inactivated mouse embryonic
ﬁbroblast (MEF) feeder cultures
All derivations and cultures of hESC lines in this study were
performed in full compliance with the Guidelines on the Derivation
and Distribution of Human Embryonic Stem Cells of the Ministry of
Education, Culture, Sports, Science and Technology, Japan (Notiﬁ-
cation No. 156 of 2009), after approval of the Institutional Review
Board regarding hESC research at the National Center for Child
Health and Development (NCCHD; “Sei-iku” in Japanese title of the
afﬁliation), Japan. Surplus frozen human embryos, donated by
consenting couples, were thawed using a Cryotop Safety Thawing
Kit (Kitazato BioPharma, Shizuoka, Japan; #VT602) according to the
manufacturer's instructions and cultured in BlastAssist System
medium (MediCult, Jyllinge, Denmark; #12150010) until they
reached the blastocyst stage. The derivation of three hESC lines, i.e.,
SEES-1, SEES-2, and SEES-3, was performed using modiﬁed HUES
derivation methods, as described previously [4,5,25]. Brieﬂy, the
inner cell mass (ICM) was isolated by immunosurgery by using
rabbit antiserum (Rockland Immunochemicals, PA, USA; #109-
4139) and guinea pig serum complement (SigmaeAldrich, MO,
USA; #S-1639) and then seeded onto a feeder layer of freshly plated
gamma-irradiated MEFs, isolated from ICR embryos at 12.5 gesta-
tions and passaged two times before gamma irradiation (30 Gy), in
hESC conventional derivation media. The hESC conventional deri-
vation media consisted of Knockout Dulbecco's modiﬁed Eagle's
medium (KO-DMEM; Life Technologies, CA, USA; #10829-018)
supplemented with 20% Knockout Serum Replacement (KO-SR;
#10828-028), 2 mM GlutaMAX-I (#35050-079), 0.1 mM nones-
sential amino acids (NEAAs; #11140-076), 50 U/mL penicillin/50 mg/
mL streptomycin (Pen-Strep; #15070-063), 0.055 mM beta-
mercaptoethanol (#21985-023), and recombinant human full-
length bFGF (#PHG0261) at 10 ng/mL (all reagents were from Life
Technologies). Seven to 14 days after ICMs were plated, expanded
ICMs were dissected mechanically into small clumps using a ﬁnely
drawn glass Pasteur pipette and transferred onto a newMEF feeder
layer as previously described [4,25]. Secondary colonies were
similarly dispersed and plated onto new feeder layers of MEFs until
passages 2e4. Cells were then further expanded manually using a
Stem Cell Cutting Tool (Vitrolife, Kungsbacka, Sweden; #14601) and
Dispase II (Eidia, Ibaraki, Japan; #GD81070).
4.2. hMSCs as feeder layers
4.2.1. Production and culture of hMSCs under XF conditions
To derive and expand hMSC feeder layers under XF conditions,
we eliminated the use of media with all animal-derived compo-
nents during the derivation, propagation, and passaging process in
the preparation of new hMSC feeders from human subjects.
Parental written informed consent was obtained from all families,
and the study was approved by the Institutional Review Board (IRB
#88) of the NCCHD. hMSCs were isolated from human dermal tis-
sue samples collected from juvenile donors undergoing surgical
procedures for polydactyly in the Division of Orthopedics of the
NCCHD. Human dermal tissues were ﬁrst washed in Dulbecco's
phosphate-buffered saline (DPBS) without calcium andmagnesium
(#14190-250) containing penicillin/streptomycin and then minced
into small pieces by using a sterile scalpel in a laminar ﬂow cabinet.
The minced tissue was centrifuged and ﬁltered in sequential steps
to separate the tissue debris. The isolated cells were then expanded
in StemPro MSC SFM XenoFree (MSC-XF; #A10675-01) supple-
mented with StemPro LipoMax Deﬁned XenoFree Lipid Supple-
ment (#A10850-01) on culture dishes coated with a recombinanthumanized matrix (CELLstart CTS; #A10142-01). The isolated cells
were expanded in MSC-XF medium with CELLstart using animal-
component free TrypLE Select (#12563-011; all reagents from Life
Technologies). After approximately 20 days, a conﬂuent monolayer
of primary cells was established (passage 0).
4.2.2. Proliferation assay
To assess the proliferative capacity of the isolated cells, primary
cultures from two donors were analyzed through 22 serial passages
using MSC-XF medium with CELLstart. Cells were counted using a
cell viability analyzer (Vi-CELL Cell Viability Analyzer; Beckman
Coulter, CA, USA), and cells were subcultured at 105 cells/100-mm
dish every 4 days for approximately 15 days. At each passage, the
population doubling (PD) rate was calculated based on the total cell
number using the following formula: [log10(Nh) e log10(N1)]/
log10(2), where N1 was the number of cells plated and Nh was the
number of cells harvested [26]. Growth curves were generated in
triplicate using two independent cell lines.
4.2.3. Flow cytometric analysis and in vitro multilineage
differentiation assay
Flow cytometric analysis was performed as described previously
[27] in order to characterize the cells. Cells were incubated with
primary antibodies or isotype-matched control antibodies, fol-
lowed by immunoﬂuorescence secondary antibody staining and
analysis using an EPICS ALTRA analyzer (Beckman Coulter). The
following cell surface epitopes were detected with anti-human
ﬂuorescein isothiocyanate (FITC)-conjugated or phycoerythrin
(PE)-conjugated antibodies: CD29 (Beckman Coulter; #6604105),
CD44 (Beckman Coulter; #IM1219), CD90 (BD Pharmingen, CA,
USA; #555596), CD117 (Beckman Coulter; #IM1360), and CD133
(Miltenyi Biotec, Bergisch Gladbach, Germany; #130-080-801). The
potential of the isolated cells to differentiate into osteogenic and
adipogenic lineages was examined according to the manufacturer's
instructions. Adipogenesis and osteogenesis were induced by
culturing cells in medium from an hMSC Adipogenic BulletKit
(Lonza, PA, USA; #PT-3004) or an hMSC Osteogenic BulletKit
(Lonza; #PT-3002), respectively. After 8 weeks under differentia-
tion conditions, cells were processed for lineage-speciﬁc staining.
Oil red staining was used for the detection of accumulated oil
droplets in the cytoplasm of cells maintained with adipogenic dif-
ferentiation media. Alkaline phosphatase activity was used to
determine the extent of osteogenesis in cells grown in osteogenic
differentiation medium.
4.2.4. Preparation of hMSCs for the feeder layer
At passages 5e20, XF cells were detached from the culture plate
with TrypLE Select, washed with MSC-XF medium, and counted.
The cells were resuspended in culture medium at a concentration
of 1107 cells per tube and then gamma-irradiatedwith 30 Gy. The
irradiated cells were washed in medium and frozen at a concen-
tration of 2  106 cells per vial in freezing medium (STEM-CELL-
BANKER, ZENOAQ, Fukushima, Japan; #CB043).
4.3. XF hESCs
4.3.1. Derivation and expansion of new hESC lines under XF
conditions
The procedure for derivation of XF hESCs was approved by the
Institutional Review Board at the NCCHD, and embryos were
collected from donors undergoing fertility treatment after obtain-
ing informed consent. Frozen embryos were thawed and cultured
to the blastocyst stage under the same methods as used for con-
ventional hESC derivation. Blastocysts without immunosurgery
were plated on inactivated XF hMSC feeder layers (Yub-1896 cells)
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Free CTS (KO-SR XF; Life Technologies; #12618-013), 85% KO-
DMED, 2 mM GlutaMAX-I, 0.1 mM NEAAs, penicillin/strepto-
mycin, 50 mg/mL L-ascorbic acid 2-phosphate (SigmaeAldrich;
#A4544), 10 ng/mL heregulin-1b, recombinant human NRG-beta 1/
HRG-beta 1 EGF domain (R&D Systems, MN, USA; #396-HB-050/
CF), 200 ng/mL LONG R3-IGF1, recombinant human insulin-like
growth factor-1 (SigmaeAldrich; #85580C), and recombinant hu-
man full-length bFGF (Life Technologies; #PHG0261) at 20 ng/mL.
Cells were initially maintained in a drawer-type incubator (IVF
CUBE, ASTEC, Fukuoka, Japan; #AR-3100) at 37 C under the
appropriate humidiﬁed gas mixture (usually 3%e5% O2/5% CO2/
90%e92% N2). Within 7 days after whole blastocysts were plated on
the feeder layers, ICMs were isolated by laser-mediated ablation of
trophectoderm (TE) cells by using a XYClone laser system (Hamil-
ton Thorne Biosciences, MA, USA) with 80% pulse strength and a
pulse length of 300 ms [5]. After 2 weeks, the ICM outgrowth began
to resemble morphologically distinct hESCs, and cells could be
handpicked and transferred to fresh plates. After the ﬁrst splitting,
new colonies were disaggregated with a recombinant trypsin
(Roche Applied Science, Basel, Switzerland; #06369880103) and
transferred to fresh mitotically inactivated XF hMSC feeder plates
every 5e7 days. Undifferentiated cells, as judged by morphology,
were chosen for each further passage. A total of four XF hESC lines
were derived and stably maintained (SEES-4, SEES-5, SEES-6, and
SEES-7). All four SEES cell lines were maintained in a standard
tissue culture incubator at 37 C under the appropriate humidiﬁed
gas mixture (3%e5% O2/5% CO2/90%e92% N2) in multigas incubator
(Sanyo, Osaka, Japan; #MCO-18M) in a separate culture room to
avoid any contamination. SEES cells were cryopreserved using a
conventional slow-rate cooling/thawing method with STEM-
CELLBANKER. Validation of the cryopreservation by subsequent
thawing of individual tubes resulted in efﬁcient recovery of viable,
undifferentiated hESCs.
4.3.2. Immunohistochemical analyses of stem cell and differentiated
markers
Immunohistochemistry was performed as previously described
[28,29]. The primary antibodies used for hESCs were speciﬁc for
Nanog (1:300; ReproCELL, Kanagawa, Japan; #RCAB0003P), Oct3/4
(1:300; Santa Cruz Biotechnology, CA, USA; #sc-5279), Sox2
(1:300; Merck Millipore, Darmstadt, Germany; #AB5603), TRA1-60
(1:300; Merck Millipore; #MAB4360), and SSEA4 (1:300; Merck
Millipore; #MAB4304). To assess the differentiation of the three
germ layers, the primary antibodies used for embryoid bodies (EBs)
were anti-a-fetoprotein (AFP; 1:200; R&D Systems; MAB1368),
mouse (ascites) anti-b-tubulin III (TUJ1; 1:1000; Promega;
#G712A), and anti-a-smooth muscle actin (aSMA; 1:400; Sigma;
#A2547). Cells were ﬁxed in 4% paraformaldehyde and incubated
with primary antibodies overnight at 4 C. Cells were then probed
with Alexa Fluor 546 Goat Anti-Mouse IgG- or Alexa Fluor 488 Goat
Anti-Rabbit IgG-conjugated secondary antibodies (1:300 each; Life
Technologies), counterstained with 1 mg/mL DAPI, for 1 h in the
dark at room temperature. After incubation, cells were mounted in
Vectashield mounting medium containing 40, 6-diamidino-2-
phenylindole (Vector Laboratories, CA, USA). The labeled cells
were visualized using a laser-scanning confocal microscope (LSM
510META; Carl Zeiss, Oberkochen, Germany). Alkaline phosphatase
(ALP) was detected with a Vector Red kit (Vector Laboratories; #SK-
5100) according to manufacturer's instructions.
4.3.3. Flow cytometry analysis of pluripotency markers
SEES cells cultured in appropriate conditions were stained for
30 min at 4 C with primary antibodies and immunoﬂuorescence
secondary antibodies. Cells were analyzed with a Cytomics FC 500Cytometer (Beckman Coulter), and data were analyzed with FC 500
CXP Software ver. 2.0 (Beckman Coulter). Antibodies against human
SSEA-1 (R&D Systems; #FAB2155C), SSEA4 (R&D Systems;
#FAB1435F), TRA1-60 (Merck Millipore; #MAB4360), and TRA1-81
(Merck Millipore; #MAB4381) were used as primary antibodies in
hESCs. PE-conjugated anti-mouse IgG antibodies (BD Pharmingen;
#555578) and PE-conjugated anti-mouse IgM antibodies (BD
Pharmingen; #553472) were used as secondary antibodies. X-
Mean, the sum of intensity divided by the total cell number, was
automatically calculated and was utilized for our evaluation.
4.3.4. Differentiation assays in vitro and in vivo
For induction of differentiation in vitro, the cells were dissoci-
ated using either StemPro Accutase (Life Technologies; #A11105-
01) or TrypLE Select for 5 min at 37 C, plated into 96-well plates
(low attachment surface; Lipidure; NOF Corp., Tokyo, Japan), and
cultured in differentiation medium containing KO-DMEM supple-
mented with 20% fetal bovine serum (FBS), 2 mM GlutaMAX-I,
0.1 mM NEAAs, and penicillin/streptomycin, to generate EBs. After
7 days in suspension, EBs were transferred onto poly-L-ornithine-
coated chamber slides and cultured for an additional 10e14 days.
The cultures were ﬁxed with 4% paraformaldehyde for 20 min
before immunohistochemical analysis.
In vivo pluripotency was assessed by teratoma formation in
severe combined immunodeﬁcient nude mice (BALB/cAJcl-nu/nu)
purchased from CLEA Japan. A 60-mm plate of undifferentiated
hESCs was washed with DPBS, and the cells were harvested with a
cell scraper. The cell suspension was collected into a 15-mL conical
tube and centrifuged at 1000 rpm for 4 min. The cell pellet was
resuspended in hESC culturemedium andMatrigel (BD Biosciences,
NJ, USA; #356234) to a ﬁnal total volume of 400 mL. Approximately
2e5  106 cells in 200 mL were injected subcutaneously into the
dorsolateral area on both sides. Mice were sacriﬁced after 8e10
weeks. Tumors were then excised surgically, ﬁxed in 4% para-
formaldehyde, embedded in parafﬁn, sectioned, and stained with
hematoxylin and eosin. Hematoxylin and eosin-stained parafﬁn-
embedded sections were histologically examined for the presence
of differentiated human tissue derived from all three embryonic
germ layers.
The animal use protocol was approved by the Institutional Animal
Care and Use Committee of the National Research Institute for Child
Health and Development (NRICHD, Permit Number: A2003-002). All
experiments with mice were subject to the 3 R consideration (reﬁne,
reduce, and replace), and all efforts were made to minimize animal
suffering and to reduce the number of animals used.
4.3.5. Sialic acid analysis
Sialic acid was released from cell homogenate samples by acid
hydrolysis with 0.05 M HCl at 80 C for 3 h. Sialic acid samples were
ultraﬁltered using Amicon Ultra-0.5 mL ﬁlters (cut-off, 10 kDa;
Millipore; #UFC503008), and ﬁltrates were dried in a vacuum
concentrator. Sialic acid was derivatized with 1,2-diamino-4,5-
methylenedioxybenzene (DMB; Sialic Acid Fluorescence Labeling
Kit; Takara Bio, Shiga, Japan) and analyzed by reverse-phase ﬂuo-
rometric HPLC1 using a PALPAK Type R column (Takara Bio). The
excitation and emission wavelengths were 310 and 448 nm,
respectively. The DMB-derivatized sialic acid was identiﬁed by
comparing retention times with those of known standards (Glyko
Sialic acid reference panel; ProZyme, CA, USA; #GKRP-2503) that
were similarly treated. This method can evaluate sialic acids at a
minimum concentration of 0.01 nmol/mg protein.
4.3.6. Karyotype analysis
Chromosomal G-band analyses were performed at the Nihon
Gene Research Laboratories, Sendai, Japan. The chromosomes were
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genetic Nomenclature. At least 20 metaphase chromosomes were
analyzed per cell line.
4.4. Generation of human iPSCs
Human iPSCs were generated from XF Yub-1896 cells by trans-
duction with of a lentiviral vector carrying three reprogramming
factors (OCT3/4, SOX2 and KLF4) under XF culture conditions. The
vector was a generous gift of Konrad Hochedlinger (Harvard Uni-
versity). XF iPSCs were successfully maintained on inactivated XF
hMSC feeder layers in XF hESC culture medium over 20 passages.
We conﬁrmed the XF iPSCs expressed pluripotent markers
including OCT3/4, NANOG, SSEA4, and TRA1-60.
4.5. Modiﬁed conventional hESC cultivation
4.5.1. Production of MEF feeder stock
Pregnant ICR mice were obtained from a breeding colony under
speciﬁc pathogen-free (SPF) conditions in a barrier room with
extensive health monitoring at CLEA Japan (Atsugi facility, Kana-
gawa, Japan). MEFs were generated from ICR embryos at 12.5 ges-
tations as previously described [5,25] and expanded using MEF
feeder sock medium composed of 90% KO-DMEM, 30 KGy gamma-
irradiated FBS (HyClone; Thermo Fisher Scientiﬁc, MA, USA), and
2 mM GlutaMAX-I without any antibiotics. At passage 2, cells were
mitotically inactivated by gamma irradiation (30 Gy) and frozen at a
concentration of 4  106 cells per vial. To minimize the risk of
introducing murine viruses and other pathogens, MEF feeder stock
was tested in GMP/GLP studies by Vitology Limited (Glasgow, UK).
The speciﬁcations and results for the testing of lot MEF-0001 are
presented in Supplemental Table 3.
4.5.2. hESC expansion using gamma-irradiated KO-SR and
pharmaceutical-grade recombinant human bFGF without
antibiotics
To develop a safer culture system for clinical application of
hESCs, we replaced KO-SR and recombinant human full-length
bFGF with pharmaceutical recombinant human bFGF and high-
dose gamma–irradiated KO-SR. Frozen KO-SR products ware
gamma irradiated at 35 KGy (KOGA ISOTOPE, Ltd., Shiga, Japan).
Pharmaceutical-grade recombinant human bFGF (generic name:
trafermin), supplied by Kaken Pharmaceutical (Tokyo, Japan) as
Fiblast Spray, which is prepared using the powdered form of tra-
fermin, was applied for hESC culture. hESC lines were cultivated in a
modiﬁed conventional culture medium composed of 20% gamma-
irradiated KO-SR, 80% KO-DMEM, 2 mM GlutaMAX-I, 0.1 mM
NEAAs, and 50 ng/mL trafermin without any antibiotics on plates
coatedwith 0.1% type I collagen (Nippon Ham, Ibaraki, Japan; #307-
31611) and a mitotically inactivated layer of MEFs.
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